Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advanz-4: Dolutegravir vs Darunavir/r in Advanced HIV
NCT02337322Phase 4Unknown
- Start
- Mar 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human immunodeficiency virus type 1 infection (HIV-1) comparing Dolutegravir Arm with Darunavir/r Arm (2 arms). Primary endpoint: Median CD4 T cell count increase at 48 weeks. Status: unknown.
02
Drugs
dolutegravirdarunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02337322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337322.